NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

兒童用醫藥品及疫苗的全球市場

Pediatric Drugs and Vaccines

出版商 Global Industry Analysts, Inc. 商品編碼 997871
出版日期 內容資訊 英文 240 Pages
商品交期: 最快1-2個工作天內
價格
兒童用醫藥品及疫苗的全球市場 Pediatric Drugs and Vaccines
出版日期: 2021年04月01日內容資訊: 英文 240 Pages
簡介

全球兒童用醫藥品及疫苗的市場規模,預計在分析期間(2020年∼2027年)將以5.8%的年複合成長率增長,從2020年的1,001億美元,到2027年達到1,488億美元。

本報告所分析的市場區隔之一的抗生素部門,分析期間中預計將以5.9%的年複合成長率增長,達到368億美元。

本報告提供全球兒童用醫藥品及疫苗市場的相關調查,提供市場佔有率,Covid-19的影響,趨勢和成長要素,各地區的市場分析,競爭情形,主要企業的簡介等資訊。

調查對象企業範例

  • Abbott Laboratories
  • Allergan Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biologics B.V
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Shionogi Inc.
  • Shire Pharmaceuticals Group Plc

目錄

I. 調查手法

II. 摘要整理

  • 市場概要
    • 影響者市場洞察
    • 全球市場的軌跡
    • Covid-19的影響與即將到來的全球景氣衰退
  • 主要企業
  • 趨勢與推動要素
  • 全球市場預測

III. 市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 南美
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他南美國家
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東
  • 非洲

IV. 競爭

  • 企業簡介:90公司

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: MCP-6503

Abstract:

Global Pediatric Drugs and Vaccines Market to Reach $148.8 Billion by 2027

Amid the COVID-19 crisis, the global market for Pediatric Drugs and Vaccines estimated at US$100.1 Billion in the year 2020, is projected to reach a revised size of US$148.8 Billion by 2027, growing at a CAGR of 5.8% over the analysis period 2020-2027. Antibiotics, one of the segments analyzed in the report, is projected to record a 5.9% CAGR and reach US$36.8 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Vaccines segment is readjusted to a revised 6.8% CAGR for the next 7-year period.

The U.S. Market is Estimated at $27.1 Billion, While China is Forecast to Grow at 8.9% CAGR

The Pediatric Drugs and Vaccines market in the U.S. is estimated at US$27.1 Billion in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$31.4 Billion by the year 2027 trailing a CAGR of 8.9% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 3.2% and 5.2% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3.7% CAGR.

Allergy & Respiratory Segment to Record 4.3% CAGR

In the global Allergy & Respiratory segment, USA, Canada, Japan, China and Europe will drive the 3.9% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$14.1 Billion in the year 2020 will reach a projected size of US$18.4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets. Led by countries such as Australia, India, and South Korea, the market in Asia-Pacific is forecast to reach US$20.1 Billion by the year 2027, while Latin America will expand at a 5.3% CAGR through the analysis period.

Select Competitors (Total 90 Featured) -

  • Abbott Laboratories
  • Allergan Inc.
  • Amgen Inc.
  • AstraZeneca Plc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Genentech Inc.
  • GlaxoSmithKline Plc
  • Janssen Biologics B.V
  • Merck & Co. Inc.
  • Novartis AG
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Sanofi
  • Shionogi Inc.
  • Shire Pharmaceuticals Group Plc

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Pediatrics: A Highly Underserved and Undervalued Group
    • Recent Market Activity
    • Pediatric Drugs Market - An Abode of Opportunities
    • The United States: Largest Market for Pediatric Drugs and Vaccines
    • Developing Markets to Witness Faster Growth
    • Antibiotics: Largest Selling Drug Classes
    • Pediatric Vaccines Market - On High Growth Trajectory
    • Supply and Demand Dynamics of the Global Vaccine Market
    • UNICEF Addresses BCG Vaccine Supply Shortage
    • Access to Vaccines Index: Aiding Increased Access to Vaccines
    • Recent Advancements/Achievements in the Pediatric Vaccines Space
    • Impact of Covid-19 and a Looming Global Recession
  • 2. FOCUS ON SELECT PLAYERS
    • Abbott Laboratories (USA)
    • Allergan, Inc. (USA)
    • Amgen, Inc. (USA)
    • AstraZeneca Plc. (UK)
    • Boehringer Ingelheim GmbH (Germany)
    • Bristol-Myers Squibb Company (USA)
    • Eli Lilly and Company (USA)
    • F. Hoffmann-La Roche Ltd (Switzerland)
    • Genentech, Inc. (USA)
    • GlaxoSmithKline plc. (UK)
    • Janssen Biologics B.V. (USA)
    • Actelion Pharmaceuticals Ltd (Switzerland) (A Janssen Pharmaceutical Company)
    • Merck & Co., Inc. (USA)
    • Novartis AG (Switzerland)
    • Novo Nordisk A/S (Denmark)
    • Pfizer, Inc. (USA)
    • Sanofi S.A (France)
    • Shionogi Inc. (USA)
    • Shire Pharmaceuticals Group Plc. (UK)
  • 3. MARKET TRENDS & DRIVERS
    • Pediatric Exclusivity Drives Manufacturers' Interest
    • Pediatric Exclusitivity Granted to Branded Drugs
    • New Product Approvals and Pipeline - A Key Growth Propeller
    • Recent Pediatric Drug Approvals: 2015-2017
    • Pediatric Drug Approvals: 2011-2014
    • Phase III Completed Pediatric Drugs: 2015-2017 (As of July 2017)
    • Ongoing Phase III Pediatric Drugs Clinical Trials: 2015-2017 (As of July 2017)
    • Potential for Pediatric Drugs Against Obesity-related Conditions
    • List of Pediatric Drugs for Congestive Heart Failure Treatment
    • Recent Findings to Help Save Children's Lives
    • Challenges of Pediatric Drug Development: Formulation Problems and Ethical Constraints of Clinical Trials
    • Financial Enticement for Drug Makers to Conduct Dedicated Pediatric Trials
    • Modeling & Simulation - A Powerful Tool for Pediatric Clinical Study Sponsors
    • Pharmacometrics Approaches Gain Traction Among US and EU Researchers
    • Challenges Associated with Adoption of Pharmacometric Approach
    • Guidelines for Conducting Ethically Correct Clinical Trials
    • Pediatric Drug Market - Is Off-label Prescription Justified?
    • Indian Drug Manufacturers Develop Pneumococcal Conjugate Vaccine
    • High Vaccination Costs: A Major Hindrance for Pneumonia Vaccination
    • Vaccine Refusal by Parents - A Growing Trend in the US Market
    • Orphan Drugs for Pediatric Use Gain Popularity
    • List of FDA Approved Orphan Drugs: 2015-2016
    • List of FDA Designated Orphan Drugs: 2015-2017
    • Pediatric Review Vouchers Foster Innovation in Rare Pediatric Drugs
    • Need for Higher Focus on Fixed-Dose Combination for Pediatric HIV Infections
    • Approved Pediatric Antiretroviral Drugs for HIV Treatment
    • Highly Fragmented Growth Hormone Market
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 2: World Historic Review for Pediatric Drugs and Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 3: World 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2012, 2020 & 2027
    • TABLE 4: World Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 5: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 6: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 7: World Current & Future Analysis for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 8: World Historic Review for Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 9: World 15-Year Perspective for Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 10: World Current & Future Analysis for Allergy & Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 11: World Historic Review for Allergy & Respiratory by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 12: World 15-Year Perspective for Allergy & Respiratory by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 13: World Current & Future Analysis for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 14: World Historic Review for CNS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 15: World 15-Year Perspective for CNS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 16: World Current & Future Analysis for Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 17: World Historic Review for Hormones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 18: World 15-Year Perspective for Hormones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027
    • TABLE 19: World Current & Future Analysis for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 20: World Historic Review for Other Therapeutic Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 21: World 15-Year Perspective for Other Therapeutic Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2012, 2020 & 2027

III. MARKET ANALYSIS

  • UNITED STATES
    • TABLE 22: USA Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 23: USA Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 24: USA 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • CANADA
    • TABLE 25: Canada Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 26: Canada Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 27: Canada 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • JAPAN
    • TABLE 28: Japan Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 29: Japan Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 30: Japan 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • CHINA
    • TABLE 31: China Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 32: China Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 33: China 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • EUROPE
    • TABLE 34: Europe Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 35: Europe Historic Review for Pediatric Drugs and Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 36: Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2012, 2020 & 2027
    • TABLE 37: Europe Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 38: Europe Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 39: Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • FRANCE
    • TABLE 40: France Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 41: France Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 42: France 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • GERMANY
    • TABLE 43: Germany Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 44: Germany Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 45: Germany 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ITALY
    • TABLE 46: Italy Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 47: Italy Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 48: Italy 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • UNITED KINGDOM
    • TABLE 49: UK Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 50: UK Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 51: UK 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • SPAIN
    • TABLE 52: Spain Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 53: Spain Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 54: Spain 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • RUSSIA
    • TABLE 55: Russia Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 56: Russia Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 57: Russia 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF EUROPE
    • TABLE 58: Rest of Europe Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 59: Rest of Europe Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 60: Rest of Europe 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ASIA-PACIFIC
    • TABLE 61: Asia-Pacific Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 62: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 63: Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2012, 2020 & 2027
    • TABLE 64: Asia-Pacific Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 65: Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 66: Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • AUSTRALIA
    • TABLE 67: Australia Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 68: Australia Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 69: Australia 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • INDIA
    • TABLE 70: India Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 71: India Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 72: India 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • SOUTH KOREA
    • TABLE 73: South Korea Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 74: South Korea Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 75: South Korea 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF ASIA-PACIFIC
    • TABLE 76: Rest of Asia-Pacific Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 77: Rest of Asia-Pacific Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 78: Rest of Asia-Pacific 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • LATIN AMERICA
    • TABLE 79: Latin America Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 80: Latin America Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 81: Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2012, 2020 & 2027
    • TABLE 82: Latin America Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 83: Latin America Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 84: Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ARGENTINA
    • TABLE 85: Argentina Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 86: Argentina Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 87: Argentina 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • BRAZIL
    • TABLE 88: Brazil Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 89: Brazil Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 90: Brazil 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • MEXICO
    • TABLE 91: Mexico Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 92: Mexico Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 93: Mexico 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF LATIN AMERICA
    • TABLE 94: Rest of Latin America Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 95: Rest of Latin America Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 96: Rest of Latin America 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • MIDDLE EAST
    • TABLE 97: Middle East Current & Future Analysis for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR
    • TABLE 98: Middle East Historic Review for Pediatric Drugs and Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 99: Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2012, 2020 & 2027
    • TABLE 100: Middle East Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 101: Middle East Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 102: Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • IRAN
    • TABLE 103: Iran Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 104: Iran Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 105: Iran 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • ISRAEL
    • TABLE 106: Israel Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 107: Israel Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 108: Israel 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • SAUDI ARABIA
    • TABLE 109: Saudi Arabia Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 110: Saudi Arabia Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 111: Saudi Arabia 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • UNITED ARAB EMIRATES
    • TABLE 112: UAE Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 113: UAE Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 114: UAE 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • REST OF MIDDLE EAST
    • TABLE 115: Rest of Middle East Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 116: Rest of Middle East Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 117: Rest of Middle East 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027
  • AFRICA
    • TABLE 118: Africa Current & Future Analysis for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR
    • TABLE 119: Africa Historic Review for Pediatric Drugs and Vaccines by Therapeutic Class - Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2012 through 2019 and % CAGR
    • TABLE 120: Africa 15-Year Perspective for Pediatric Drugs and Vaccines by Therapeutic Class - Percentage Breakdown of Value Sales for Antibiotics, Vaccines, Allergy & Respiratory, CNS, Hormones and Other Therapeutic Classes for the Years 2012, 2020 & 2027

IV. COMPETITION

  • Total Companies Profiled: 90